Browse by Journal Title

2021

Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? - A preclinical assessment in vitro and in vivo.
Briest, F., Koziolek, E.J., Albrecht, J., Schmidt, F., Bernsen, M.R., Haeck, J., Kühl, A.A., Sedding, D., Hartung, T., Exner, S., Welzel, M., Fischer, C., Grötzinger, C., Brenner, W., Baum, R.P. and Grabowski, P.
Neoplasia 23 (1): 80-98. January 2021

Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
Rivera, M., Fichtner, I., Wulf-Goldenberg, A., Sers, C., Merk, J., Patone, G., Alp, K.M., Kanashova, T., Mertins, P., Hoffmann, J., Stein, U. and Walther, W.
Neoplasia 23 (1): 21-35. January 2021

2011

Intervening in beta-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis.
Stein, U., Arlt, F., Smith, J., Sack, U., Herrmann, P., Walther, W., Lemm, M., Fichtner, I., Shoemaker, R.H. and Schlag, P.M.
Neoplasia 13 (2): 131-144. February 2011

2004

Chromosomal alterations during lymphatic and liver metastasis formation of colorectal cancer [Erratum in: Neoplasia. vol 6, pg 686, 2004].
Knoesel, T., Schluens, K., Stein, U., Schwabe, H., Schlag, P.M., Dietel, M. and Petersen, I.
Neoplasia 6 (1): 23-28. 1 January 2004

2001

Magnetic labeling of activated microglia in experimental gliomas.
Fleige, G., Nolte, C., Synowitz, M., Seeberger, F., Kettenmann, H. and Zimmer, C.
Neoplasia 3 (6): 489-499. 1 January 2001